NCT03373435 - Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2018

Primary Completion Date

January 30, 2019

Study Completion Date

March 15, 2019

Conditions

Postbariatric Hypoglycemia

Interventions

DRUG

exendin 9-39

Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.

OTHER

Placebo

Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.

Trial Locations (5)

Johns Hopkins University, Baltimore

Duke Early Phase Clinical Research, Durham

University of Wisconsin, Madison

University of Colorado, Denver, Aurora

Stanford University, Palo Alto